Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis

EBioMedicine. 2016 Feb 9:4:7-8. doi: 10.1016/j.ebiom.2016.02.016. eCollection 2016 Feb.

Authors

Bintou Ahmadou Ahidjo¹, William R Bishai²

Affiliations

¹ Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.

No abstract available

Publication types

Comment

MeSH terms

Antitubercular Agents / therapeutic use
Cyclic AMP
Humans
Mycobacterium tuberculosis
Phosphodiesterase 3 Inhibitors
Phosphodiesterase 4 Inhibitors / therapeutic use
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors*
Tuberculosis / drug therapy*

Substances

Antitubercular Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase 4 Inhibitors
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Cyclic AMP